This company listing is no longer active
ASPC.Q Stock Overview
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Acerus Pharmaceuticals Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.22 |
| 52 Week High | US$7.42 |
| 52 Week Low | US$0.22 |
| Beta | 0.47 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -97.23% |
| 3 Year Change | -96.76% |
| 5 Year Change | -99.60% |
| Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| ASPC.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 2.7% |
| 1Y | -97.2% | 12.9% | 26.0% |
Return vs Industry: ASPC.Q underperformed the US Pharmaceuticals industry which returned -1.4% over the past year.
Return vs Market: ASPC.Q underperformed the US Market which returned -8.3% over the past year.
Price Volatility
| ASPC.Q volatility | |
|---|---|
| ASPC.Q Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ASPC.Q has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ASPC.Q's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 14 | Ed Gudaitis | www.aceruspharma.com |
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis.
Acerus Pharmaceuticals Corporation Fundamentals Summary
| ASPC.Q fundamental statistics | |
|---|---|
| Market cap | US$1.69m |
| Earnings (TTM) | -US$28.08m |
| Revenue (TTM) | US$3.04m |
0.6x
P/S Ratio-0.1x
P/E RatioIs ASPC.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASPC.Q income statement (TTM) | |
|---|---|
| Revenue | US$3.04m |
| Cost of Revenue | US$1.33m |
| Gross Profit | US$1.71m |
| Other Expenses | US$29.79m |
| Earnings | -US$28.08m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.64 |
| Gross Margin | 56.32% |
| Net Profit Margin | -924.33% |
| Debt/Equity Ratio | -329.8% |
How did ASPC.Q perform over the long term?
See historical performance and comparison